The anti-VEGF antibody bevacizumab and mTORC1 inhibitor everolimus showed only limited efficacy, leading to moderate (T/C < 25%) to strong responses (T/C < 10%) and stable tumor volumes (RTV 0.34-1.7) in 7 and 4 out of 26 models, respectively. The gene discussed is VEGFA; the disease is neoplasm.